CAN10 Counters Scleroderma Development in Preclinical Study

CAN10 Counters Scleroderma Development in Preclinical Study

315447

CAN10 Counters Scleroderma Development in Preclinical Study

Cantargia’s investigational antibody treatment, CAN10, showed promise in an animal model of systemic sclerosis (or scleroderma), normalizing several biological indicators of disease and counteracting disease development in the skin and lungs. “We are excited about these new results, showing strong effects of CAN10 in a systemic sclerosis model. Cantargia is committed to develop new therapies for life-threatening diseases and we look forward to advance this promising project to treatment of patients,” Göran Forsberg, Cantargia CEO,…

You must be logged in to read/download the full post.